Descripción de la empresa
Karyopharm Therapeutics Inc. operates as a commercial-stage pharmaceutical entity dedicated to the discovery, development, and commercialization of drugs targeting nuclear export mechanisms for the treatment of cancer and other diseases within the United States. The company functions within the Healthcare sector, specifically in the Biotechnology industry, a domain characterized by high R&D intensity and significant regulatory hurdles before products reach the market. Its current scale is defined by a market capitalization of $162.54M, annual revenue of $146.07M, and an employee base of 228 individuals. These financial metrics indicate that the company maintains a mid-market capitalization typical of biotechnology firms that are actively generating revenue but have not yet achieved profitability, suggesting a position where commercialization efforts are underway while still navigating the capital-intensive phases of drug development.
Salud financiera
The company reported a trailing twelve-month revenue of $146.07M, yet recorded a net income of $-196,039,008 and an EBITDA of $-90,411,000, revealing a substantial gap between top-line generation and bottom-line profitability driven by significant operating expenses and likely research costs. This negative net income relative to revenue indicates that the cost structure involves high overhead or development expenditures that currently exceed the gross profits generated from sales. Free cash flow stands at $-49,426,500, which implies that the company is burning through its cash reserves to fund operations and growth initiatives, limiting immediate financial flexibility for large-scale acquisitions or aggressive expansion without further capital raising. Margin analysis shows a gross margin of 9.9%, an operating margin of -52.4%, and a profit margin of -134.2%, illustrating that while the core production of drugs retains some value, the overall operational model incurs heavy losses that erode profitability significantly. On the balance sheet, the company holds $63.74M in cash against total debt of $305.94M, and since the debt-to-equity ratio is listed as N/A, the leverage profile is heavily weighted toward liabilities rather than equity. The current ratio of 1.12 suggests that the company possesses just enough current assets to cover its short-term liabilities, indicating a tight liquidity position that requires careful management of working capital. Return on Equity and Return on Assets are both listed as N/A or negative, specifically an ROA of -41.6%, which reveals that management has not yet been effective in generating positive returns on the capital base deployed to run the business.
Evaluación de valoración
Valuation metrics for Karyopharm present a complex picture given the lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -1.65, implying that earnings expectations are currently negative and the market is pricing in a path to future profitability rather than current performance. The price-to-book ratio is -0.45, indicating that the market values the company at a discount to its book value, a common characteristic for biotech firms with substantial intangible assets or potential liabilities that are not fully reflected in the accounting book value. Alternative valuation multiples such as the price-to-sales ratio of 1.11 and an EV/EBITDA of -4.14 suggest that investors are valuing the company primarily on its revenue generation potential rather than current earnings power. In terms of trading range, the 52-week high is $10.99 and the 52-week low is $3.65, meaning the current price sits at a point where the stock has experienced significant volatility, having lost over 66% of its value from the high mark. The beta value of 0.40 indicates that the stock's price volatility is significantly lower than the broader market, suggesting it may be less sensitive to general market movements compared to large-cap equities.
Growth & Income
The company demonstrated a revenue growth year-over-year of 11.6%, while earnings growth is listed as N/A due to the negative net income, highlighting that revenue expansion is occurring without corresponding earnings improvement, which is typical for pre-profitability stages but implies that profitability will need to be achieved before earnings growth can be tracked. As a non-dividend payer, the company does not distribute a dividend yield or payout ratio, as these metrics are listed as N/A and 0.0% respectively, indicating that all available earnings and cash flows are being retained within the company to fund operations and research. This reinvestment strategy is standard for biotechnology firms that prioritize capital allocation toward drug development pipelines over shareholder income distributions. The overall growth and income profile reflects a revenue-positive, cash-negative entity that relies on organic sales growth to eventually cross the threshold into profitability, rather than offering current income or mature earnings growth.